February 8, 2005 -- While the broad markets moved slightly higher, biotech took a breather on Tuesday, moving more than one-half percent lower. The Centient Biotech 200 dropped 22.29 points to 3448.06, a .64% loss, while the NYSE Composite was .09% higher and Nasdaq was up .22%. In today’s report, we look at another clinical trial setback for Maxim (which took the stock 20% lower), Pfizer’s cancer drug that looks good, acquisitions for Invitrogen and Genzyme, a nasal spray for female sexual dysfunction from Palatin, and solid Q4 results for Elan. We give more detail...
